Retinal Neovascularization
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C & D
This activity is supported by an educational grant from Opthea.
Six biomarkers predict AMD progression with greater certainty than ‘large drusen’ sign
Researchers have identified biomarkers that predict age-related macular degeneration progression as well as biomarkers associated with progression to geographic atrophy and neovascularization, according to a review published in Ophthalmology Retina.